Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Decrease in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 84,500 shares, a decrease of 49.6% from the February 13th total of 167,500 shares. Based on an average daily volume of 432,500 shares, the short-interest ratio is currently 0.2 days. Currently, 3.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP acquired a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.17% of the company’s stock.

Theriva Biologics Stock Performance

NYSEAMERICAN:TOVX traded up $0.04 during trading hours on Friday, hitting $1.15. The stock had a trading volume of 38,411 shares, compared to its average volume of 155,790. Theriva Biologics has a one year low of $1.03 and a one year high of $17.11. The stock has a market cap of $3.21 million, a P/E ratio of -0.03 and a beta of 1.22. The firm has a 50 day moving average price of $1.47.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.